Background: This study aimed to compare the live function change and adverse events (AEs) between drug-eluting beads (DEB) transarterial chemoembolization (TACE) with CalliSpheres microspheres (CSM) and conventional TACE (cTACE) in treating hepatocellular carcinoma (HCC) patients.

Methods: Three hundred and thirty-five HCC patients underwent DEB-TACE with CSM (n=171, DEB-TACE group) or cTACE (n=164, cTACE group) were consecutively enrolled in this multi-center, retrospective cohort study. Liver function indexes were reviewed before treatment (W0), at 1 week (W1) and 1 month (M1) post treatment. Moreover, AEs during operation and hospitalization were retrieved as well.

Results: The changes of albumin (ALB) [-3.55 (-6.25 to -0.43) -2.20 (-4.63-0.00), P=0.043] and total protein (TP) [-4.62 (-10.18-0.43) -2.50 (-7.08-1.08), P=0.013] from W1 to W0 were lower in DEB-TACE group compared to cTACE group, while no difference was observed referring to the change of alanine aminotransferase (ALT) (P=0.494), aspartate aminotransferase (AST) (P=0.747), alkaline phosphatase (ALP) (P=0.895), total bilirubin (TBIL) (P=0.059), total bile acid (TBA) (P=0.491) from W1 to W0. And the changes of these seven indexes from M1 to W0 were all similar between DEB-TACE group and cTACE group (all P>0.05). Besides, the occurrence of pain during treatment (19.3% 11.0%, P=0.034) and the occurrence of fever during hospitalization (18.1% 9.1%, P=0.017) were both increased in DEB-TACE group compared to cTACE group.

Conclusions: DEB-TACE with CSM is non-inferior to cTACE in terms of liver function change, while DEB-TACE with CSM leads to higher incidences of pain and fever.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799233PMC
http://dx.doi.org/10.21037/tcr.2019.09.15DOI Listing

Publication Analysis

Top Keywords

deb-tace group
16
liver function
12
deb-tace csm
12
ctace group
12
deb-tace
8
ctace
8
multi-center retrospective
8
retrospective cohort
8
cohort study
8
function change
8

Similar Publications

Objective: To investigate the efficacy and safety of drug-eluting beads transcatheter arterial chemoembolization(DEB-TACE) combined with systemic chemotherapy and immune checkpoint inhibitors in the treatment of unresectable intrahepatic cholangiocarcinoma.

Methods: This study used retrospective cohort analysis to collect the clinical data of 209 patients with unresectable intrahepatic cholangiocarcinoma treated in Linyi Cancer Hospital, Affiliated Zhongshan Hospital of Dalian University, Affiliated Central Hospital of Dalian University of Technology from January 2020 to January 2024. The patients were divided into observation group and control group based on their treatment plans.

View Article and Find Full Text PDF

Background: This case series evaluated the clinical impact and significant technical points of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using the smaller drug-eluting bead (DEB) M1 (DC Bead M1; 70-150 µm).

Methods: We evaluated 12 patients and 14 HCC nodules treated with DEB-TACE using the DC Bead M1 (named DEM1-TACE). In addition to evaluating the early treatment efficacy for each treated node after DEM1-TACE, the study also used interventional radiology (IVR)- computed tomography (CT) to focus on the presence or absence of retention of the homogeneous contrast medium in target nodules after DEM1-TACE as a predictor of a good treatment response.

View Article and Find Full Text PDF

Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer.

World J Gastrointest Oncol

December 2024

State Key Laboratory of Internal Medicine of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100700, China.

Background: Transhepatic arterial chemoembolization (TACE), as a local treatment, has been widely used in the treatment of unresectable liver cancer. The introduction of drug carrier microspheres has brought new hope for the therapeutic effect of TACE. Microspheres can realize the slow release and directional delivery of drugs, reduce systemic toxicity and improve local curative effect.

View Article and Find Full Text PDF

Purpose: The aim of this study was to assess the safety and effectiveness of transarterial chemoembolization (TACE) plus lenvatinib with a programmed death-1 (PD-1) inhibitor compared with TACE plus lenvatinib and TACE alone for hepatocellular carcinoma (HCC) with the hepatic vein and/or inferior vena cava tumor thrombus (HVTT and IVCTT).

Methods: Data on HCC accompanied by HVTT and IVCTT from June 2015 to August 2022 were analyzed in this single-center retrospective study. Drug-eluting bead TACE (DEB-TACE) or conventional TACE (cTACE) was used.

View Article and Find Full Text PDF
Article Synopsis
  • Transcatheter arterial chemoembolization (TACE) is a key treatment for patients with primary hepatocellular carcinoma (PHC) who cannot have surgery, with two types: conventional TACE (c-TACE) and drug-eluting bead TACE (DEB-TACE), each having different characteristics that affect their effectiveness.
  • A study analyzed outcomes of DEB-TACE and c-TACE in PHC patients, using propensity-score matching to ensure balanced comparison, with 86 patients in each group after matching.
  • Results showed DEB-TACE had better clinical efficacy, with higher objective response and disease control rates, as well as improved liver function post-treatment, indicating it may be a more effective option for treating PHC
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!